Episode Description
We follow rapamycin from a soil sample on Easter Island to the center of longevity science, then break down how mTOR decides between growth and repair. We also confront the “friendly fire” problem that shows up with chronic dosing and explain why current trials focus on precision pulsing and measurable biomarkers.
• the 1975 discovery story and why rapamycin was shelved then revived for organ transplantation
• how TOR genes led to mTOR and why phosphorylation changes protein shape and function
• mTOR as a nutrient and energy sensor integrating leucine, arginine, ATP, oxygen, and insulin
• why nonstop mTORC1 activity links to senescence, SASP inflammation, and age-related decline
• how rapamycin inhibits mTORC1 to unlock autophagy and act as a calorie restriction mimetic
• what mTORC2 does for cell survival and why losing it can wreck glucose control
• animal evidence across species including late-life mouse benefits and sex differences
• why companion dog trials matter and what improved heart function suggests
• the Fang study logic behind insulin resistance with chronic exposure and later adaptation
• how human trials use intermittent dosing plus epigenetic clocks, cytokines, metabolic labs, and functional tests
Keep questioning the world around you. Keep an eye on those clinical trials, and don’t forget to let yourselves take out the trash.
This podcast is created by Ai for educational and entertainment purposes only and does not constitute professional medical or health advice. Please talk to your healthcare team for medical advice.
Never miss an episode—subscribe on your favorite podcast app!